Literature DB >> 9560205

Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs.

L Gorman1, D Suter, V Emerick, D Schümperli, R Kole.   

Abstract

In several forms of beta-thalassemia, mutations in the second intron of the beta-globin gene create aberrant 5' splice sites and activate a common cryptic 3' splice site upstream. As a result, the thalassemic beta-globin pre-mRNAs are spliced almost exclusively via the aberrant splice sites leading to a deficiency of correctly spliced beta-globin mRNA and, consequently, beta-globin. We have designed a series of vectors that express modified U7 snRNAs containing sequences antisense to either the aberrant 5' or 3' splice sites in the IVS2-705 thalassemic pre-mRNA. Transient expression of modified U7 snRNAs in a HeLa cell line stably expressing the IVS2-705 beta-globin gene restored up to 65% of correct splicing in a sequence-specific and dose-dependent manner. Cell lines that stably coexpressed IVS2-705 pre-mRNA and appropriately modified U7 snRNA exhibited up to 55% of permanent restoration of correct splicing and expression of full-length beta-globin protein. This novel approach provides a potential alternative to gene replacement therapies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9560205      PMCID: PMC20190          DOI: 10.1073/pnas.95.9.4929

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene.

Authors:  M Sadelain; C H Wang; M Antoniou; F Grosveld; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

2.  Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.

Authors:  J D Thompson; D F Ayers; T A Malmstrom; T L McKenzie; L Ganousis; B M Chowrira; L Couture; D T Stinchcomb
Journal:  Nucleic Acids Res       Date:  1995-06-25       Impact factor: 16.971

3.  3' end processing of mouse histone pre-mRNA: evidence for additional base-pairing between U7 snRNA and pre-mRNA.

Authors:  C Spycher; A Streit; B Stefanovic; D Albrecht; T H Koning; D Schümperli
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

4.  A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis.

Authors:  M R Knowles; K W Hohneker; Z Zhou; J C Olsen; T L Noah; P C Hu; M W Leigh; J F Engelhardt; L J Edwards; K R Jones
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

5.  Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies.

Authors:  G D Sher; G D Ginder; J Little; S Yang; G J Dover; N F Olivieri
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

6.  In vivo generation of highly abundant sequence-specific oligonucleotides for antisense and triplex gene regulation.

Authors:  S B Noonberg; G K Scott; M R Garovoy; C C Benz; C A Hunt
Journal:  Nucleic Acids Res       Date:  1994-07-25       Impact factor: 16.971

7.  Direct selection for mutations affecting specific splice sites in a hamster dihydrofolate reductase minigene.

Authors:  I T Chen; L A Chasin
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

8.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

Authors:  Z Dominski; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial.

Authors:  A F Collins; H A Pearson; P Giardina; K T McDonagh; S W Brusilow; G J Dover
Journal:  Blood       Date:  1995-01-01       Impact factor: 22.113

10.  The low abundance of U7 snRNA is partly determined by its Sm binding site.

Authors:  C Grimm; B Stefanovic; D Schümperli
Journal:  EMBO J       Date:  1993-03       Impact factor: 11.598

View more
  40 in total

1.  Sensitivity of splice sites to antisense oligonucleotides in vivo.

Authors:  H Sierakowska; M J Sambade; D Schümperli; R Kole
Journal:  RNA       Date:  1999-03       Impact factor: 4.942

Review 2.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

3.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

Review 4.  The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy.

Authors:  Qi-Long Lu; Toshifumi Yokota; Shin'ichi Takeda; Luis Garcia; Francesco Muntoni; Terence Partridge
Journal:  Mol Ther       Date:  2010-10-26       Impact factor: 11.454

5.  U7 snRNA-mediated correction of aberrant splicing caused by activation of cryptic splice sites.

Authors:  Hideki Uchikawa; Katsunori Fujii; Yoichi Kohno; Noriyuki Katsumata; Kazuaki Nagao; Masao Yamada; Toshiyuki Miyashita
Journal:  J Hum Genet       Date:  2007-09-13       Impact factor: 3.172

6.  Targeting the splicing of mRNA in autoimmune diseases: BAFF inhibition in Sjögren's syndrome as a proof of concept.

Authors:  N Roescher; J L Vosters; G Alsaleh; P Dreyfus; S Jacques; G Chiocchia; J Sibilia; P P Tak; J A Chiorini; X Mariette; Jacques-Eric Gottenberg
Journal:  Mol Ther       Date:  2013-12-05       Impact factor: 11.454

7.  Intracellular generation of single-stranded DNA for chromosomal triplex formation and induced recombination.

Authors:  H J Datta; P M Glazer
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

Review 8.  Producing recombinant adeno-associated virus in foster cells: overcoming production limitations using a baculovirus-insect cell expression strategy.

Authors:  Tamas Virag; Sylvain Cecchini; Robert M Kotin
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

9.  Localizing the RPGR protein along the cilium: a new method to determine efficacies to treat RPGR mutations.

Authors:  R Da Costa; E Glaus; A Tiwari; B Kloeckener-Gruissem; W Berger; J Neidhardt
Journal:  Gene Ther       Date:  2015-01-29       Impact factor: 5.250

10.  Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting cyclophilin A.

Authors:  Songkai Liu; Maria Asparuhova; Vincent Brondani; Ingrid Ziekau; Thomas Klimkait; Daniel Schümperli
Journal:  Nucleic Acids Res       Date:  2004-07-14       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.